Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Alarming rise in ...

The Rheumatoid Arthritis Drugs/Therapeutics market revenue was $$ Million USD in 2022, grew to $$ Million USD in 2024, and will reach $$ Million USD in 2032, with a CAGR of $% during 2024-2032.

Rheumatoid arthritis ... For example, some drugs cause a person to bruise more easily or be more sensitive to sunlight, according to the Arthritis Foundation. One of the key symptoms can be ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

It is currently being evaluated for the treatment of systemic lupus erythematosus ... "Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial" was originally created ...